Filing Flows › Karyopharm Therapeutics (KPTI) › Q4 2025
Karyopharm Therapeutics (KPTI) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Feb 13, 2026
Karyopharm Therapeutics (KPTI) reported revenue of $34.1M for the fourth quarter 2025 (Q4 2025), +12% from a year earlier and -23% from the quarter before. Operating margin was -52.4%, net loss $102M (299.9% of revenue).
Karyopharm Therapeutics, Q4 2025: revenue $34.1M (+12% year over year), operating margin -52.4%, net loss $102M, operating cash flow −$11.8M. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $34.1M | -23% | +12% |
| Operating profit | −$17.8M | — | — |
| Net earnings | −$102M | — | — |
| Operating cash flow | −$11.8M | — | — |
What changed
Revenue was $34.1M in Q4 2025, up 12% year over year and down 23% from the previous quarter. Product was the largest line at 94% of revenue.
Operating costs exceeded revenue by $17.8M, an operating margin of -52.4%. Total costs fell 16% while revenue rose 12%. The fastest-growing cost line was Other operating costs (+11%). The quarter ended with a net loss of $102.2M, wider than the previous quarter's $33.1M loss. Net interest and other expense of $84.4M was the main reason.
Operating cash flow was −$11.8M. Non-cash charges added back $19K of depreciation and $3.9M of share-based compensation. Working capital and other items added $86.4M.
Questions
What was Karyopharm Therapeutics' revenue in the fourth quarter 2025?
Karyopharm Therapeutics (KPTI) reported revenue of $34.1M for the fourth quarter 2025 (Q4 2025), +12% from a year earlier and -23% from the quarter before.
Was Karyopharm Therapeutics profitable in the fourth quarter 2025?
Operating loss was $17.8M (-52.4% of revenue) and net loss $102M.